1Banting FG, Best CH, Collip JB, et al. (1922) Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 12, 141–146.
2Abel JJ (1926) Crystalline insulin. Proc Natl Acad Sci U S A 12, 132–136.
3Scott DA (1934) Crystalline insulin. Biochem J 28, 1592–1602.
4Scott DA & Fisher AM (1935) The effect of zinc salts on the action of insulin. J Pharmacol Exp Ther 55, 206–211.
5Scott DA & Fisher AM (1938) The insulin and the zinc content of normal and diabetic pancreas. J Clin Invest 17, 725–728.
6Sanger F (1949) Species differences in insulins. Nature 164, 524–529.
7Brown H, Sanger F & Kitai R (1955) The structure of pig and sheep insulins. Biochem J 60, 556–565.
8Adams MJ, Blundell TL, Dodson GG, et al. (1969) Structure of rhombohedral 2 zinc insulin crystals. Nature 224, 491–495.
9Rabinowitch IM, Foster JS, Fowler AF, et al. (1936) Clinical experiences with protamine–zinc–insulin and other mixtures of zinc and insulin in diabetes mellitus. Can Med Assoc J 35, 239–252.
10Rabinowitch IM, Fowler AF & Corcoran AC (1937) Further observations on the use of protamine zinc insulin in diabetes mellitus. Can Med Assoc J 36, 111–129.
11Lacey AH (1952) A comparison of preparations of NPH insulin. J Pharmacol Exp Ther 105, 196–202.
12Becker RH & Frick AD (2008) Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 47, 7–20.
13Anderson JH & Campbell RK (1990) Mixing insulins in 1990. Diabetes Educ 16, 380–387.
14Planchart A (1965) Potentiation of insulin action by calcium and magnesium. Diabetes 14, 430–431.
15Devis G, Somers G, Van Obberghen E, et al. (1975) Calcium antagonists and islet function. I. Inhibition of insulin release by verapamil. Diabetes 24, 247–251.
16Grynkiewicz G, Poenie M & Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260, 3440–3450.
17Henquin JC (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49, 1751–1760.
18Zalewski PD, Forbes IJ & Betts WH (1993) Correlation of apoptosis with change in intracellular labile Zn(II) using zinquin [(2-methyl-8-p-toluenesulphonamido-6-quinolyloxy)acetic acid], a new specific fluorescent probe for Zn(II). Biochem J 296, 403–408.
19Zalewski PD, Millard SH, Forbes IJ, et al. (1994) Video image analysis of labile zinc in viable pancreatic islet cells using a specific fluorescent probe for zinc. J Histochem Cytochem 42, 877–884.
20Palmiter RD & Findley SD (1995) Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. EMBO J 14, 639–649.
21Palmiter RD, Cole TB & Findley SD (1996) ZnT-2, a mammalian protein that confers resistance to zinc by facilitating vesicular sequestration. EMBO J 15, 1784–1791.
22Palmiter RD, Cole TB, Quaife CJ, et al. (1996) ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci U S A 93, 14934–14939.
23Grotz N, Fox T, Connolly E, et al. (1998) Identification of a family of zinc transporter genes from Arabidopsis that respond to zinc deficiency. Proc Natl Acad Sci U S A 95, 7220–7224.
24Eide DJ (2004) The SLC39 family of metal ion transporters. Pflugers Arch 447, 796–800.
25Burdette SC, Walkup GK, Spingler B, et al. (2001) Fluorescent sensors for Zn2+ based on a fluorescein platform: synthesis, properties and intracellular distribution. J Am Chem Soc 123, 7831–7841.
26Lichten LA & Cousins RJ (2009) Mammalian zinc transporters: nutritional and physiologic regulation. Annu Rev Nutr 29, 153–176.
27Cousins RJ & Lichten LA (2011) Zinc transporters. In Zinc in Human Health, pp. 136–162 [Rink L, editor]. Amsterdam: IOS Press.
28Plum LM, Rink L & Haase H (2010) The essential toxin: impact of zinc on human health. Int J Environ Res Public Health 7, 1342–1365.
29Kim BE, Wang F, Dufner-Beattie J, et al. (2004) Zn2+-stimulated endocytosis of the mZIP4 zinc transporter regulates its location at the plasma membrane. J Biol Chem 279, 4523–4530.
30Taylor KM, Hiscox S, Nicholson RI, et al. (2012) Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Sci Signal 5, ra11.
31Beharier O, Dror S, Levy S, et al. (2012) ZnT-1 protects HL-1 cells from simulated ischemia–reperfusion through activation of Ras-ERK signaling. J Mol Med (Berl) 90, 127–138.
32Kury S, Dreno B, Bezieau S, et al. (2002) Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet 31, 239–240.
33Kiechl-Kohlendorfer U, Fink FM & Steichen-Gersdorf E (2007) Transient symptomatic Zn deficiency in a breast-fed preterm infant. Pediatr Dermatol 24, 536–540.
34Yang L, Li H, Yu T, et al. (2008) Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications. Am J Physiol Endocrinol Metab 294, E987–E992.
35Sladek R, Rocheleau G, Rung J, et al. (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881–885.
36Kambe T (2011) An overview of a wide range of functions of ZnT and Zip zinc transporters in the secretory pathway. Biosci Biotechnol Biochem 75, 1036–1043.
37Dodson G & Steiner D (1998) The role of assembly in insulin's biosynthesis. Curr Opin Struct Biol 8, 189–194.
38Foster MC, Leapman RD, Li MX, et al. (1993) Elemental composition of secretory granules in pancreatic islets of Langerhans. Biophys J 64, 525–532.
39Ishihara H, Maechler P, Gjinovci A, et al. (2003) Islet β-cell secretion determines glucagon release from neighbouring α-cells. Nat Cell Biol 5, 330–335.
40Dunn MF (2005) Zinc–ligand interactions modulate assembly and stability of the insulin hexamer – a review. Biometals 18, 295–303.
41Wijesekara N, Chimienti F & Wheeler MB (2009) Zinc, a regulator of islet function and glucose homeostasis. Diabetes Obes Metab 11, Suppl. 4, 202–214.
42Kambe T, Narita H, Yamaguchi-Iwai Y, et al. (2002) Cloning and characterization of a novel mammalian zinc transporter, zinc transporter 5, abundantly expressed in pancreatic β cells. J Biol Chem 277, 19049–19055.
43Smidt K, Rungby J, et al. (2012) ZnT3: a zinc transporter active in several organs. Biometals 25, 1–8.
44Smidt K, Jessen N, Petersen AB, et al. (2009) SLC30A3 responds to glucose- and zinc variations in β-cells and is critical for insulin production and in vivo glucose-metabolism during β-cell stress. PLoS One 4, e5684.
45Petersen AB, Smidt K, Magnusson NE, et al. (2011) siRNA-mediated knock-down of ZnT3 and ZnT8 affects production and secretion of insulin and apoptosis in INS-1E cells. APMIS 119, 93–102.
46Chimienti F, Devergnas S, Favier A, et al. (2004) Identification and cloning of a β-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 53, 2330–2337.
47Smidt K, Pedersen SB, Brock B, et al. (2007) Zn-transporter genes in human visceral and subcutaneous adipocytes: lean versus obese. Mol Cell Endocrinol 264, 68–73.
48Murgia C, Devirgiliis C, Mancini E, et al. (2009) Diabetes-linked zinc transporter ZnT8 is a homodimeric protein expressed by distinct rodent endocrine cell types in the pancreas and other glands. Nutr Metab Cardiovasc Dis 19, 431–439.
49Chimienti F, Devergnas S, Pattou F, et al. (2006) In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci 119, 4199–4206.
50Zeggini E, Weedon MN, Lindgren CM, et al. (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316, 1336–1341.
51Nicolson TJ, Bellomo EA, Wijesekara N, et al. (2009) Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. Diabetes 58, 2070–2083.
52Dupuis J, Langenberg C, Prokopenko I, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42, 105–116.
53Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39, 770–775.
54Staiger H, Machicao F, Stefan N, et al. (2007) Polymorphisms within novel risk loci for type 2 diabetes determine β-cell function. PLoS ONE 2, e832.
55Kang ES, Kim MS, Kim YS, et al. (2008) A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 57, 1043–1047.
56Pare G, Chasman DI, Parker AN, et al. (2008) Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. PLoS Genet 4, e1000312.
57Cauchi S, Del Guerra S, Choquet H, et al. (2010) Meta-analysis and functional effects of the SLC30A8 rs13266634 polymorphism on isolated human pancreatic islets. Mol Genet Metab 100, 77–82.
58Lemaire K, Ravier MA, Schraenen A, et al. (2009) Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. Proc Natl Acad Sci U S A 106, 14872–14877.
59Pound LD, Sarkar S, Benninger RK, et al. (2009) Deletion of the mouse Slc30a8 gene encoding zinc transporter-8 results in impaired insulin secretion. Biochem J 421, 371–376.
60Wijesekara N, Dai FF, Hardy AB, et al. (2010) Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion. Diabetologia 53, 1656–1668.
61Fu Y, Tian W, Pratt EB, et al. (2009) Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion. PLoS ONE 4, e5679.
62Hardy AB, Wijesekara N, Genkin I, et al. (2012) Effects of high-fat diet feeding on Znt8-null mice: differences between β-cell and global knockout of Znt8. Am J Physiol Endocrinol Metab 302, E1084–E1096.
63Islam MS & du Loots T (2007) Diabetes, metallothionein, and zinc interactions: a review. Biofactors 29, 203–212.
64Maret W (2011) Redox biochemistry of mammalian metallothioneins. J Biol Inorg Chem 16, 1079–1086.
65Levadoux M, Mahon C, Beattie JH, et al. (1999) Nuclear import of metallothionein requires its mRNA to be associated with the perinuclear cytoskeleton. J Biol Chem 274, 34961–34966.
66Chen H, Carlson EC, Pellet L, et al. (2001) Overexpression of metallothionein in pancreatic β-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 50, 2040–2046.
67Park L, Min D, Kim H, et al. (2011) Tat-enhanced delivery of metallothionein can partially prevent the development of diabetes. Free Radic Biol Med 51, 1666–1674.
68Maret W & Vallee BL (1998) Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci U S A 95, 3478–3482.
69Stitt MS, Wasserloos KJ, Tang X, et al. (2006) Nitric oxide-induced nuclear translocation of the metal responsive transcription factor, MTF-1 is mediated by zinc release from metallothionein. Vascul Pharmacol 44, 149–155.
70Giacconi R, Bonfigli AR, Testa R, et al. (2008) +647 A/C and +1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications. Mol Genet Metab 94, 98–104.
71Giacconi R, Cipriano C, Muti E, et al. (2005) Novel –209A/G MT2A polymorphism in old patients with type 2 diabetes and atherosclerosis: relationship with inflammation (IL-6) and zinc. Biogerontology 6, 407–413.
72Mocchegiani E, Giacconi R & Malavolta M (2008) Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes. Trends Mol Med 14, 419–428.
73Seve M, Chimienti F & Favier A (2002) Role of intracellular zinc in programmed cell death. Pathol Biol (Paris) 50, 212–221.
74Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40, 405–412.
75Chang I, Cho N, Koh JY, et al. (2003) Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes. Diabetologia 46, 1220–1227.
76Bellomo EA, Meur G & Rutter GA (2011) Glucose regulates free cytosolic Zn2+ concentration, Slc39 (ZiP), and metallothionein gene expression in primary pancreatic islet β-cells. J Biol Chem 286, 25778–25789.
77Lieberman SM & DiLorenzo TP (2003) A comprehensive guide to antibody and T-cell responses in type 1 diabetes. Tissue Antigens 62, 359–377.
78Haase H & Rink L (2009) Functional significance of zinc-related signaling pathways in immune cells. Annu Rev Nutr 29, 133–152.
79Wenzlau JM, Juhl K, Yu L, et al. (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 104, 17040–17045.
80Vaziri-Sani F, Oak S, Radtke J, et al. (2010) ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 43, 598–606.
81Énée E, Kratzer R, Arnoux JB, et al. (2012) ZnT8 is a major CD8+T cell-recognized autoantigen in pediatric type 1 diabetes. Diabetes 61, 1779–1784.
82Gohlke H, Ferrari U, Koczwara K, et al. (2008) SLC30A8 (ZnT8) polymorphism is associated with young age at type 1 diabetes onset. Rev Diabet Stud 5, 25–27.
83Kerr-Conte J, Vandewalle B, Moerman E, et al. (2010) Upgrading pretransplant human islet culture technology requires human serum combined with media renewal. Transplantation 89, 1154–1160.
84Okamoto T, Kuroki T, Adachi T, et al. (2011) Effect of zinc on early graft failure following intraportal islet transplantation in rat recipients. Ann Transplant 16, 114–120.
85Coulston L & Dandona P (1980) Insulin-like effect of zinc on adipocytes. Diabetes 29, 665–667.
86May JM & Contoreggi CS (1982) The mechanism of the insulin-like effects of ionic zinc. J Biol Chem 257, 4362–4368.
87Yoshikawa Y, Adachi Y, Yasui H, et al. (2011) Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-Ay mice: structure–activity relationship on zinc–salicylate complexes. Chem Pharm Bull (Tokyo) 59, 972–977.
88Adachi Y, Yoshida J, Kodera Y, et al. (2006) Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes. Biochem Biophys Res Commun 351, 165–170.
89Cameron AR, Anil S, Sutherland E, et al. (2010) Zinc-dependent effects of small molecules on the insulin-sensitive transcription factor FOXO1a and gluconeogenic genes. Metallomics 2, 195–203.
90Basuki W, Hiromura M & Sakurai H (2007) Insulinomimetic Zn complex (Zn(opt)2) enhances insulin signaling pathway in 3T3-L1 adipocytes. J Inorg Biochem 101, 692–699.
91Haase H & Maret W (2005) Fluctuations of cellular, available zinc modulate insulin signaling via inhibition of protein tyrosine phosphatases. J Trace Elem Med Biol 19, 37–42.
92Haase H, Maret W, et al. (2005) Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. Biometals 18, 333–338.
93Wilson M, Hogstrand C & Maret W (2012) Picomolar concentrations of free zinc(II) ions regulate receptor protein-tyrosine phosphatase β activity. J Biol Chem 287, 9322–9326.
94Gyulkhandanyan AV, Lee SC, Bikopoulos G, et al. (2006) The Zn2+-transporting pathways in pancreatic β-cells: a role for the L-type voltage-gated Ca2+ channel. J Biol Chem 281, 9361–9372.
95Gromada J, Franklin I & Wollheim CB (2007) α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28, 84–116.
96Hardy AB, Serino AS, Wijesekara N, et al. (2011) Regulation of glucagon secretion by zinc: lessons from the β cell-specific Znt8 knockout mouse model. Diabetes Obes Metab 13, Suppl. 1, 112–117.
97Sensi SL, Paoletti P, Bush AI, et al. (2009) Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 10, 780–791.
98Franklin I, Gromada J, Gjinovci A, et al. (2005) β-Cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54, 1808–1815.
99Ravier MA & Rutter GA (2005) Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic α-cells. Diabetes 54, 1789–1797.
100Robertson RP, Zhou H & Slucca M (2011) A role for zinc in pancreatic islet β-cell cross-talk with the α-cell during hypoglycaemia. Diabetes Obes Metab 13, Suppl. 1, 106–111.
101Chausmer AB (1998) Zinc, insulin and diabetes. J Am Coll Nutr 17, 109–115.
102Garg VK, Gupta R & Goyal RK (1994) Hypozincemia in diabetes mellitus. J Assoc Physicians India 42, 720–721.
103de Sena KC, Arrais RF, das Gracas Almeida M, et al. (2005) Effects of Zn supplementation in patients with type 1 diabetes. Biol Trace Elem Res 105, 1–9.
104Jansen J, Rosenkranz E, Overbeck S, et al. (2012) Disturbed zinc homeostasis in diabetic patients by in vitro and in vivo analysis of insulinomimetic activity of zinc. J Nutr Biochem 23, 1458–1466.
105Chimienti F, Rutter GA, Wheeler MB, et al (2011) Zinc and diabetes. In Zinc in Human Health, pp. 493–513 [Rink L, editor]. Amsterdam: IOS Press.
106Jayawardena R, Ranasinghe P, Galappatthy P, et al. (2012) Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 4, 13.
107Simon SF & Taylor CG (2001) Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp Biol Med (Maywood) 226, 43–51.
108Begin-Heick N, Dalpe-Scott M, Rowe J, et al. (1985) Zinc supplementation attenuates insulin secretory activity in pancreatic islets of the ob/ob mouse. Diabetes 34, 179–184.
109Niewoehner CB, Allen JI, Boosalis M, et al. (1986) Role of zinc supplementation in type II diabetes mellitus. Am J Med 81, 63–68.
110Raz I, Karsai D & Katz M (1989) The influence of zinc supplementation on glucose homeostasis in NIDDM. Diabetes Res 11, 73–79.
111Hegazi SM, Ahmed SS, Mekkawy AA, et al. (1992) Effect of zinc supplementation on serum glucose, insulin, glucagon, glucose-6-phosphatase and mineral levels in diabetics. J Clin Biochem Nutr 12, 209–215.
112Gunasekara P, Hettiarachchi M, Liyanage C, et al. (2011) Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes. Diabetes Metab Syndr Obes 4, 53–60.
113Gupta R, Garg VK, Mathur DK, et al. (1998) Oral zinc therapy in diabetic neuropathy. J Assoc Physicians India 46, 939–942.
114Hayee MA, Mohammad QD & Haque A (2005) Diabetic neuropathy and zinc therapy. Bangladesh Med Res Counc Bull 31, 62–67.
115Marchesini G, Bugianesi E, Ronchi M, et al. (1998) Zinc supplementation improves glucose disposal in patients with cirrhosis. Metabolism 47, 792–798.
116Al-Maroof RA & Al-Sharbatti SS (2006) Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi Med J 27, 344–350.
117Hussain SA, Khadim HM, Khalaf BH, et al. (2006) Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J 27, 1483–1488.
118Faure P, Benhamou PY, Perard A, et al. (1995) Lipid peroxidation in insulin-dependent diabetic patients with early retina degenerative lesions: effects of an oral zinc supplementation. Eur J Clin Nutr 49, 282–288.
119Anderson RA, Roussel AM, Zouari N, et al. (2001) Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr 20, 212–218.
120Roussel AM, Kerkeni A, Zouari N, et al. (2003) Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. J Am Coll Nutr 22, 316–321.
121Garcia-Medina JJ, Pinazo-Duran MD, Garcia-Medina M, et al. (2011) A 5-year follow-up of antioxidant supplementation in type 2 diabetic retinopathy. Eur J Ophthalmol 21, 637–643.
122Wei W, Liu Q, Tan Y, et al. (2009) Oxidative stress, diabetes, and diabetic complications. Hemoglobin 33, 370–377.
123Kanoni S, Nettleton JA, Hivert MF, et al. (2011) Total zinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: a 14-cohort meta-analysis. Diabetes 60, 2407–2416.